S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Bed Bath & Beyond Is Circling the Drain
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Institutions are Buying up Procter & Gamble Shares, Should you?

Helius Medical Technologies - HSDT Stock Forecast, Price & News

$0.37
-0.01 (-2.65%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.36
$0.38
50-Day Range
$0.22
$0.41
52-Week Range
$0.20
$4.76
Volume
208,585 shs
Average Volume
909,124 shs
Market Capitalization
$10.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Helius Medical Technologies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,258.7% Upside
$5.00 Price Target
Short Interest
Healthy
3.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$22,810 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.75) to ($0.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.42 out of 5 stars

Medical Sector

169th out of 1,053 stocks

Electromedical Equipment Industry

4th out of 24 stocks


HSDT stock logo

About Helius Medical Technologies (NASDAQ:HSDT) Stock

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational Portable Neuromodulation Stimulator (PoNS), that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA.

Receive HSDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Helius Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

HSDT Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
See More Headlines
Receive HSDT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Helius Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

HSDT Company Calendar

Last Earnings
11/14/2022
Today
2/01/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSDT
Fax
N/A
Employees
19
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,258.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-18,130,000.00
Net Margins
-1,741.55%
Pretax Margin
-1,741.55%

Debt

Sales & Book Value

Annual Sales
$763,000.00
Book Value
$2.98 per share

Miscellaneous

Free Float
25,039,000
Market Cap
$10.38 million
Optionable
Not Optionable
Beta
1.02

Key Executives

  • Dane Carl AndreeffDane Carl Andreeff
    President, Chief Executive Officer & Director
  • Jeffrey S. MathiesenJeffrey S. Mathiesen
    CFO, Secretary, Treasurer & Director
  • Antonella Favit-van Pelt
    Chief Medical Officer
  • Frederick Fantazzia
    VP-Sales & Marketing North America Region
  • Lawrence Picciano
    SVP-Engineering, Quality & Regulatory Affairs













HSDT Stock - Frequently Asked Questions

Should I buy or sell Helius Medical Technologies stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Helius Medical Technologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSDT shares.
View HSDT analyst ratings
or view top-rated stocks.

What is Helius Medical Technologies' stock price forecast for 2023?

2 Wall Street analysts have issued 12-month price objectives for Helius Medical Technologies' stock. Their HSDT share price forecasts range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 1,258.7% from the stock's current price.
View analysts price targets for HSDT
or view top-rated stocks among Wall Street analysts.

How have HSDT shares performed in 2023?

Helius Medical Technologies' stock was trading at $0.3069 at the start of the year. Since then, HSDT shares have increased by 19.9% and is now trading at $0.3680.
View the best growth stocks for 2023 here
.

When is Helius Medical Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our HSDT earnings forecast
.

How were Helius Medical Technologies' earnings last quarter?

Helius Medical Technologies, Inc. (NASDAQ:HSDT) announced its quarterly earnings data on Monday, November, 14th. The company reported ($0.12) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.12. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.13 million. Helius Medical Technologies had a negative net margin of 1,741.55% and a negative trailing twelve-month return on equity of 148.27%.

When did Helius Medical Technologies' stock split?

Helius Medical Technologies's stock reverse split on Thursday, December 31st 2020. The 1-35 reverse split was announced on Thursday, December 31st 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 4th 2021. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What guidance has Helius Medical Technologies issued on next quarter's earnings?

Helius Medical Technologies issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $275.00K-$285.00K, compared to the consensus revenue estimate of $280.00K.

What is Helius Medical Technologies' stock symbol?

Helius Medical Technologies trades on the NASDAQ under the ticker symbol "HSDT."

How do I buy shares of Helius Medical Technologies?

Shares of HSDT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Helius Medical Technologies' stock price today?

One share of HSDT stock can currently be purchased for approximately $0.37.

How much money does Helius Medical Technologies make?

Helius Medical Technologies (NASDAQ:HSDT) has a market capitalization of $10.38 million and generates $763,000.00 in revenue each year. The company earns $-18,130,000.00 in net income (profit) each year or ($3.55) on an earnings per share basis.

How can I contact Helius Medical Technologies?

Helius Medical Technologies' mailing address is 642 NEWTOWN YARDLEY ROAD SUITE 100, NEWTOWN PA, 18940. The official website for the company is heliusmedical.com. The company can be reached via phone at (215) 944-6100 or via email at bbapty@heliusmedical.com.

This page (NASDAQ:HSDT) was last updated on 2/2/2023 by MarketBeat.com Staff